Arcturus Therapeutics Holdings Inc. 8-K

What Happened
Arcturus Therapeutics Holdings, Inc. (ARCT) filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on June 5, 2026. A quorum was present (21,435,189 of 28,423,069 shares entitled to vote). Stockholders elected the board nominees listed in the proxy, approved the non‑binding “say-on-pay” advisory vote on executive compensation, and ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the 2026 fiscal year.

Key Details

• Meeting date: June 5, 2026. Total shares entitled to vote: 28,423,069; shares present (in person or by proxy): 21,435,189 (quorum).
• Board elections (For / Withhold / Broker Non‑Votes):
  • Dr. Peter Farrell: 15,641,369 / 116,895 / 5,676,925
  • Joseph E. Payne: 15,660,970 / 97,294 / 5,676,925
  • James Barlow: 15,618,263 / 140,001 / 5,676,925
  • Dr. Edward W. Holmes: 15,521,066 / 237,198 / 5,676,925
  • Dr. Magda Marquet: 15,616,156 / 142,108 / 5,676,925
  • Dr. Jing L. Marantz: 15,626,241 / 132,023 / 5,676,925
  • Dr. John H. Markels: 15,633,667 / 124,597 / 5,676,925
  • Dr. Moncef Slaoui: 15,643,492 / 114,772 / 5,676,925
  • Each nominee listed in the proxy was elected to hold office until the 2027 annual meeting.
• Say-on-pay (non‑binding advisory vote): For 15,254,240; Against 327,647; Abstain 176,375; Broker Non‑Votes 5,676,927 — the proposal was approved.
• Ratification of auditor (Deloitte & Touche LLP): For 21,378,017; Against 46,823; Abstain 10,349 — appointment ratified.

Why It Matters
These voting results confirm governance continuity: the company’s listed board nominees were re‑elected and shareholders endorsed executive compensation in a non‑binding vote. Ratification of Deloitte as auditor finalizes the firm responsible for auditing Arcturus’ 2026 financial statements. For investors, these outcomes reduce near‑term governance uncertainty and clarify who will oversee company strategy and financial reporting through the next annual meeting.